Subscribe
Share
Share
Embed
McKinsey's $2.7T wellness archetype framework, new menopause brain research, Europe's top healthtech funders in H1 2026, and German diabetes nutrition guidance.
McKinsey just handed supplement and functional food brands a data-backed targeting framework for a $2.7 trillion market — and new neuroscience on menopause is opening a cognitive health opportunity that's barely been touched.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Big show today — four stories worth clearing your morning for.
Klara: McKinsey just dropped a new framework on wellness consumer archetypes, and it's genuinely useful for targeting.
Marco: Then we're looking at new neuroscience on menopause and the brain — real ingredient opportunity there.
Klara: Plus Europe's most-funded healthtech companies in H1 2026.
Marco: And updated German clinical guidance on Type 2 diabetes that functional food brands need to see.
Klara: Let's get into it.
Marco: McKinsey has just published a major segmentation framework identifying five distinct consumer archetypes behind the $2.7 trillion global wellness industry.
Marco: Wellness is no longer one category with one type of buyer. Consumers are coming to supplements, functional foods, and health services from completely different starting points — different fears, different motivations, different price tolerances. For years, brands have been treating them as one homogenous group.
Marco: McKinsey partner Anna Pione co-authored this new report. It maps five archetypes — ranging from proactive health optimisers, who are essentially performance-driven self-trackers, all the way to cost-conscious well-being seekers, who want the benefit but are watching every penny. Each group has distinct purchase triggers. The $2.7 trillion figure covers the full global wellness market today.
Marco: From a commercial standpoint, this is exactly the kind of boardroom ammunition European brands need right now. If you're trying to justify a bigger wellness budget internally, walking in with a McKinsey-validated $2.7 trillion market figure changes the conversation immediately.
Klara: That's useful context. But I want to flag something for European marketers specifically. Knowing your archetype doesn't change what health claims you're legally allowed to make. Under EU regulation EC 1924/2006, only EFSA-authorised claims can appear in marketing — and those are quite narrow. So if your archetype is the proactive optimiser who responds to performance language, you still can't overpromise. The framework tells you *who* to talk to. EFSA still controls *what* you can say.
Marco: That's a real constraint. I'd actually argue it's also an opportunity — brands that learn to speak authentically within those regulatory limits will build more durable consumer trust than brands that push boundaries and get pulled up.
Klara: Agreed on that. Right — let's turn to our next story.
Klara: New neuroscience is fundamentally changing how we understand what menopause does to the brain — and that has real implications for supplement brands.
Klara: For a long time, the menopause supplement market focused heavily on hot flushes and bone density. Brain health sat at the edges. But cognitive symptoms — brain fog, memory lapses, mood shifts — are among the most reported and most distressing experiences for women going through this transition. They just haven't received the same scientific attention.
Klara: That's now shifting. Researchers have identified that hormonal changes during menopause trigger structural and neurological shifts that are considerably more significant than previously assumed. This isn't just about oestrogen dropping. The brain itself appears to reorganise in ways that affect cognition and mental health in measurable, lasting ways. No single study has closed the debate, but the direction of the evidence is becoming hard to ignore.
Klara: From a science standpoint, this opens the door for nutritional interventions — but carefully. EFSA-authorised claims around cognitive function exist for certain ingredients, like omega-3 DHA, B vitamins, and iodine. Brands wanting to connect these ingredients to menopause-specific brain health will need to stay within those approved claims and avoid suggesting their product treats or prevents any neurological condition.
Marco: Commercially, this is a category waiting to be properly claimed. The menopause market is already accelerating across European retail — Holland & Barrett, dm, pharmacies — but the brain health angle is genuinely underdeveloped. Women over 45 are highly health-engaged and research-driven. A brand that shows up with credible, science-backed cognitive positioning — not just mood-washing — has a real opportunity to own that space.
Klara: Though I'd caution against racing to market before the science is more settled. Building on preliminary findings is exactly how brands end up with messaging they can't defend.
Marco: Fair enough — and frankly, the brands that wait for the evidence to consolidate and then communicate it clearly will be more trusted than the first movers who overreach. Let's move to our next story.
Marco: Tech EU has just published its ranking of Europe's ten most-funded healthtech companies in the first half of 2026.
Marco: European healthtech doesn't exist in a vacuum from the broader supplement and wellness world. Where institutional capital flows signals which health categories investors consider durable bets — and that shapes competitive expectations across the whole sector.
Marco: The picture from H1 2026 is striking. Investment concentrated heavily in biotechnology, medical devices, and AI-powered health applications. The top ten collectively pulled in substantial funding rounds at a time when broader venture markets are cautious. What's notable isn't just the volume — it's the pattern. Capital is bifurcating. A small number of high-conviction companies are attracting enormous rounds, while early-stage companies are finding it harder to raise. The funding map is narrowing.
Klara: From a science standpoint, this makes sense. Biotech and medical devices operate in regulated frameworks with demonstrable clinical evidence requirements. Investors understand those validation pathways. Consumer health and nutraceuticals are murkier — the evidence bar is lower, but so is the defensibility. The question for supplement brands watching this data is whether they're building the kind of clinical and regulatory infrastructure that institutional capital will recognise.
Marco: That's exactly where I'd push back slightly. The gap between supplement brand and health platform is closing faster than most founders realise. Brands that layer diagnostics, digital tools, or personalisation on top of their products are starting to look more like the companies attracting these large rounds. The funding benchmark is rising — supplement brands that don't evolve their positioning will increasingly look like the smaller, undifferentiated players that aren't getting funded.
Klara: The science still has to underpin that positioning. Technology doesn't substitute for evidence.
Marco: Noted. Now, let's move to our final story.
Klara: Updated German clinical guidance on Type 2 diabetes therapy has just reinforced nutritional intervention as a core pillar of metabolic health management — and that matters well beyond Germany's borders.
Klara: Type 2 diabetes management has long been dominated by pharmaceutical conversations. GLP-1 drugs — the injectable weight-loss and blood sugar medications you'll have seen across health headlines — have absorbed enormous attention lately. Meanwhile, the nutritional side of the equation has been somewhat overshadowed.
Klara: This new guidance from Ernährungs Umschau changes that framing. The updated German nutritional medicine recommendations make two things explicit. First, treatment must be tailored to individual lifestyle circumstances — there is no single protocol that fits everyone. Second, nutritional intervention sits alongside pharmacological treatment as a foundational approach, not a secondary one. That's a meaningful clinical endorsement of dietary and nutraceutical strategies in metabolic health.
Klara: For brands, this matters scientifically because it draws on evidence-backed practice within a credible clinical framework. It doesn't hand brands a licence to make medical claims — in Germany, as across the EU, disease treatment claims on foods and supplements remain prohibited. But it does provide legitimate context for communicating metabolic health positioning to healthcare professionals and pharmacies.
Marco: Commercially, the timing is excellent. German pharmacy and healthcare professional channels are sophisticated and evidence-driven. Brands that can demonstrate alignment with current clinical thinking — not just cite generic research — will carry considerably more weight in those conversations. This guidance gives nutritional brands a credible counter-narrative to the pharmaceutical framing that's dominated metabolic health for the past two years.
Klara: Though I'd stress that alignment means substance, not just messaging. If a brand wants to show up in a clinical channel, the product formulation has to be able to withstand scrutiny.
Marco: That's the bar worth building to.
Marco: If there's one thing today made clear, it's that specificity sells — the brands that know exactly who they're talking to, what that person's biology is doing, and what the evidence actually supports are the ones pulling ahead.
Klara: And the evidence bar keeps rising, so build your claims on solid ground now, not later.